← Back
Data updated: Jul 17, 2026
WHARTON LABS
Generics Pharmaceuticals
WHARTON LABS is a generic drug manufacturer with 1 FDA-approved products.
1973
Since
1
Drugs
-
Trials
0
New Drugs (2yr)
WHARTON LABS's Key Drugs
WHARTON LABS's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).
No active drugs
WHARTON LABS's Recent FDA Approvals
New NDA/BLA approvals for WHARTON LABS over the last two years — novel drugs only, excluding generics and label supplements.
No recent approvals
WHARTON LABS's Therapeutic Areas
Disease areas where WHARTON LABS has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.
No indication data
WHARTON LABS Pipeline Snapshot
Active clinical trials for WHARTON LABS across all therapeutic areas, from ClinicalTrials.gov.
No active pipeline data available
Pro Expected Approvals & Milestones
Loading detailed analysis...
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Top drug revenue breakdown
- • Drug-level revenue analysis
Trial Catalysts
- • Active trial monitoring
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Unlock Full Intelligence
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 1973-11-13
- Latest
- 1973-11-13
- Applications
- 1